SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
T/FIF Portfolio
An SI Board Since August 1998
Posts SubjectMarks Bans
1073 31 0
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
673 London, March 8 (Blooberg) -- The U.S. biotechnology industry could suffer fromLLCF-3/8/1999
672 more OT...FBIOX Sepracor holdings... 526,800 shares 8/31/97 (James Harmon starMike McFarland-3/7/1999
671 Some of the Fidelity funds' success has been their SEPR holding, which theytnsaf-3/7/1999
670 But FBIOX still suffers from rapid turnover of it's managers--about once aMike McFarland-3/7/1999
669 SMH: Great observation....... week after week, Fidelity Select Biotech contiscaram(o)uche-3/7/1999
668 :-) I've used the phrase here at SI myself, and.... curiously, I picked iscaram(o)uche-3/7/1999
667 RH, FBIOX results are at least presentable. There has to be a large unmet neesmh-3/6/1999
666 Third tier = "roach motel" stocks Thought I might get a rise out of smh-3/6/1999
665 Sounds like everything is pretty well tracking together...even the micros as a Mike McFarland-3/6/1999
664 The week that was...... Fidelity Selects: Biotch 43.35 42.65 27.01 scaram(o)uche-3/6/1999
663 My two cents on big cap pharma and the WSJ article... Message 8163137 MessageMike McFarland-3/5/1999
662 The discrepancy in market cap between the product-rich companies and the third-scaram(o)uche-3/4/1999
661 Too many times have I read an article in the Journal which pointed in one dirMike McFarland-3/4/1999
660 >>anyone who has worked at a pharma will read [today's WSJ] article aRCMac-3/4/1999
659 Correct...... pharma is not competitive, and realizes that what I've beenscaram(o)uche-3/4/1999
658 <. Validates INCY, MLNM, and GENXY> Both MLNM and INCY (Randy Scott) coLLCF-3/4/1999
657 >> Also... front page WSJ Big Pharma fights back in gene hunting game! WOscaram(o)uche-3/4/1999
656 Being a cheese head (& Alum) maybe I should suggest some stocks to these guLLCF-3/4/1999
655 <<Do you think NBIX burned a little credibility as a serious CNS researchMiljenko Zuanic-3/3/1999
654 < NBIX > Got into this one today... we're just about cash value herLLCF-3/3/1999
653 <. I do like the model potential and the manner in which the business plan iLLCF-3/3/1999
652 Good points, Miljenko, that NBIX didn't burn a lot of money of DHEA and thaJohn Metcalf-3/3/1999
651 I've been a long-term critic of IMGN's business plan and the fashion inscaram(o)uche-3/3/1999
650 To those following IMGN here, this morning they issued a press release on a PatGary Mohilner-3/3/1999
649 Hi Gang, Is it Hype or is it sound scientific understanding with a high likeliBRAVEHEART-3/3/1999
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News